SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
Article
Eichelberg, Christian, Vervenne, Walter L., De Santis, Maria, Fischer von Weikersthal, Ludwig, Goebell, Peter J., Lerchenmüller, Christian, Zimmermann, Uwe, Bos, Monique M.E.M., Freier, Werner, Schirrmacher-Memmel, Silke, Staehler, Michael, Pahernik, Sascha, Los, Maartje, Schenck, Marcus, Flörcken, Anne, van Arkel, Cornelis, Hauswald, Kirsten, Indorf, Martin, Gottstein, Dana and Michel, Maurice S. (2015) SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. European Urology 68 (5), pp. 837-847.Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | European Urology | ||||
| Publisher | ELSEVIER SCIENCE BV | ||||
| Place of Publication | AMSTERDAM | ||||
| Volume | 68 | ||||
| Number of Issue or Book Chapter | 5 | ||||
| Page Range | pp. 837-847 | ||||
| Date | 2015 | ||||
| Date of publication | 19 Dec 2024 07:22 | ||||
| Institutions | Medicine > Lehrstuhl für Urologie | ||||
| Identification Number |
| ||||
| Keywords | PHASE-III TRIAL; ELDERLY-PATIENTS; ANTITUMOR-ACTIVITY; 2ND-LINE THERAPY; INTERFERON-ALPHA; POOLED ANALYSIS; CARCINOMA; TEMSIROLIMUS; PROGRESSION; STRATEGIES; Renal cell carcinoma; Sequential therapy; Sorafenib; Sunitinib | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 59985 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric